Loading
A phase 3 trial of Lazertinib, Amivantamab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure is a phase 3 interventional study registered as NCT04988295 by Janssen Research & Development, LLC, with 776 participants enrolled, started 2021-11-17 and due to reach its primary completion in 2023-07-10. Interventions recorded: Lazertinib, Amivantamab, Pemetrexed and Carboplatin. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
776 enrolled.
95% CI 6.77 to 9.10; Figures from the ClinicalTrials.gov results section (first posted 2025-04-16), not from a publication · 95% CI 4.04 to 4.44 · 95% CI 5.55 to 8.41
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)primary | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | 263 | 8.31 months | - | - | link |
| Main Study: Arm B: Carboplatin + Pemetrexed (CP) | 263 | 4.17 months | ||||
| Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) | 131 | 6.28 months |
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Pemetrexed and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.